A vaccine created using artificial intelligence that could potentially provide broader protection against multiple coronaviruses and help prepare for future outbreaks has passed its first human clinical trial. Researchers from the Universities of Cambridge and Southampton developed a ‘universal vaccine’ designed to protect against multiple Sarbeco coronaviruses.

Traditional Vaccines vs. AI-Designed Vaccines

Traditional vaccines must constantly be updated as viruses mutate, and the process is ‘like a dog chasing its tail,’ said University of Southampton professor Saul Faust, the trial’s chief investigator. The trial of the vaccine proved safe and triggered an immune response in 39 healthy volunteers, marking ‘the first time that a vaccine whose active component was designed entirely by computer simulations has been tested in humans,’ the release said.

The trial vaccine was administered through a micro-fluid jet that delivers the immunization through the skin using a tiny, high-pressure stream of liquid and does not require a needle. The researchers said this method could make it ‘faster and easier to carry out in large numbers of people.’ Some experts have raised broad concerns about using AI in medicine, primarily when it comes to making clinical decisions, not developing vaccines.

Original reporting: Fox News (HLL/CB) — read the source article.